New Two-Drug combo aims to beat back returning myeloma

NCT ID NCT07463807

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The goal is to see if the new combo is safe and can lower cancer cells to undetectable levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teclistamab and pomalidomide
What this could lead to: If successful, this could offer a more effective, fixed-duration treatment option for people with multiple myeloma that has come back after initial therapy.
What could go wrong: This is an early-phase (Ib/II) trial with a small number of participants, so results may not apply broadly. The new combination may cause side effects or not work better than the standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

ECOG-ACRIN Cancer Research Group
RECRUITING

Philadelphia, Pennsylvania, 19103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.